ALCL patients without ALK translocations cannot be treated by ALK inhibitors and have a worse prognosis compared to ALCL, ALK+ patients creating an urgent need for new and refined molecularly targeted therapeutic options for ALCL [15, 17, 18]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.